Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics GlobeNewswire - Mon Dec 16, 7:00AM CST

SNTI : 3.97 (-0.25%)
Senti Biosciences Announces New Employment Inducement Grants GlobeNewswire - Tue Dec 3, 7:00PM CST

SNTI : 3.97 (-0.25%)
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study Zacks Investment Research - Tue Dec 3, 11:14AM CST

Senti Biosciences, Inc. SNTI announced positive initial data from a phase I study that evaluated its chimeric antigen receptor natural killer (CAR-NK) cell therapy candidate, SENTI-202, for the treatment...

IMCR : 28.33 (-0.33%)
SNTI : 3.97 (-0.25%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Senti Biosciences Reports Positive Initial clinical Results for SENTI-202 in Phase 1 Trial for Relapsed/Refractory AML Quiver Quantitative, Inc. - Mon Dec 2, 4:16PM CST

Two out of three patients achieved complete remission in a clinical trial for a novel AML cell therapy.Quiver AI SummarySenti Biosciences, Inc. announced positive early results from its Phase 1 clinical...

SNTI : 3.97 (-0.25%)
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed Stocktwits - Mon Dec 2, 12:50PM CST

The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.

SNTI : 3.97 (-0.25%)
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing GlobeNewswire - Mon Dec 2, 6:10AM CST

SNTI : 3.97 (-0.25%)
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML GlobeNewswire - Mon Dec 2, 6:02AM CST

SNTI : 3.97 (-0.25%)
Senti Bio Appoints Fran Schulz to Board of Directors GlobeNewswire - Mon Dec 2, 6:00AM CST

SNTI : 3.97 (-0.25%)
Senti Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Clinical Updates Quiver Quantitative, Inc. - Fri Nov 15, 1:20AM CST

Senti Bio reports Q3 2024 financial results, highlighting clinical progress for SENTI-202 and grant funding from CIRM.Quiver AI SummarySenti Biosciences, Inc. announced its third-quarter 2024 financial...

SNTI : 3.97 (-0.25%)
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights GlobeNewswire - Thu Nov 14, 3:05PM CST

SNTI : 3.97 (-0.25%)

Barchart Exclusives

Why This Solar Stock Is a Tariff Winner to Buy for 2025 Barchart - 14 minutes ago
First Solar could be the "sole" beneficiary of new U.S. anti-dumping tariffs on countries like Vietnam and Malaysia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot